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1. Introduction  
1.1 Incidence and prevalence 
Atrial fibrillation (AF) and its consequences are today’s main epidemiologic concerns. Two 
most important population based studies, the Framingham Study and the Rotterdam Study, 
report a lifetime risk of developing AF as one in four people after the age of 40 years. This is 
opposed to breast cancer which affects one in eight women, or heart failure affecting every 
fifth individual. (Lloyd-Jones et al., 2004, Mattace-Raso et al., 2006) With aging population, 
both AF prevalence and incidence are also increasing. (Lakatta & Levy, 2003b) AF represents 
the most common, highly prevalent cardiac arrhythmia which is the strongest risk factor for 
ischemic stroke, currently affecting 4,5 to 6 million Europeans and 2,3 to 5,1 million 
Americans. The prevalence of AF ranges from 2,5% in individuals over 40 yrs of age, 6% in 
those older than 65, to 12-16% in those over 75 yrs. (Lloyd-Jones et al., 2004; Stewart et al., 
2002; Wolf et al., 1991; Kannnel et al., 2008; Miyasaka et al., 2006) AF affects more than 1% of 
the population in total, and 70% of AF patients are aged between 65 and 85 yrs. (Phillips et 
al., 1990) This number is expected to double in the next 30 years. (Miyasaka et al., 2006; 
Savelieva & Camm, 2001; Go et al., 2008).  
1.2 AF burden 
AF also represents a great burden both for the patient and the society. AF symptoms 
(palpitations, fatigue, chest pain, dizziness, light headedness, syncope and dyspnoea) have a 
strong negative impact on patients’ quality of life, regardless of their frequency or duration. 
(Fuster et al., 2006; Van den Berg et al., 2005) Studies have shown that 68% of patients find 
AF symptoms disruptive, and 30% suffer an associated anxiety or depression. (Hamer et al., 
1994; Thrall et al., 2007) AF accounts for more hospitalizations than any other arrhythmia. 
Society wise, AF represents a great public health issue which is expected to increase over the 
next decades due to aging population and improved cardiac disease management. In 1995, 
there were more than 1,6 million consultations, and more than 59000 hospitalizations due to 
AF. (Stewart et al., 2002)  In Denmark alone, this number has increased by 60% in the last 20 
years. (Friberg et al., 2003). 
2. AF – risk for stroke and dementia occurrence 
AF is the commonest sustained cardiac rhythm disorder, and is encountered in everyday 
clinical practice.  Irrespective of whether we use a rate-control or rhythm-control strategy, 
stroke prevention with appropriate thromboprophylaxis still remains central to the 
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management of this common arrhythmia.  When strokes occur in AF patients, the risk of 
mortality and disability, as well as recurrent stroke is substantially much higher. (Lip & 
Halperin, 2010) 
Additionally, AF as the most common arrhythmia in the elderly is becoming more frequently 
evaluated in various studies. Furthermore, Leibovitch has pointed out, in his review article, 
that the most important issues to treat in the very elderly are hypertension and AF. (2008) 
AF is a potentially dangerous condition for the development of two very serious 
neurological conditions: stroke and dementia. Those two conditions are the leading causes 
of mortality and disability in the developed countries and also in the developing world as 
estimated in 2010 by World Health Organizations. (Shirwany et Zou, 2010)  
The risk of stroke is increased five-fold in individuals with AF. (Wolf et al., 1991) However, 
it often passes on unnoticed until its gloomy consequences are discovered. Appearently, 
about 20% of ischemic stroke patients have AF, based on their admission electrocardiogram 
(ECG). (Kimura et al., 2004; Liao et al., 2007) Additionally, AF seems to be even more 
important than hypertension in stroke aetiology of the very old. (Marengoni et al., 2009; 
Ratcliffe et Wilcock, 1985) And, silent or asymptomatic AF unfortunately carries the same 
long-term risk for stroke, just like for symptomatic patients. (Page et al., 2003) Continuous 
ECG monitoring can register up to 40% of cases, where a pacemaker reading can reveal as 
much as 88% of cases. Namely, a Scottish population study showed that for both women 
and men, there was a significant increase in all-cause mortality, cardiovascular events, fatal 
or nonfatal stroke, and heart failure. (Stewart et al., 2002; Benjamin et al., 1998) Regardless 
whether it is paroxysmal or persistent AF, risk of stroke is similar (Atrial Fibrillation 
Investigators, 1994) since there is a high risk of recurrence and conversion of paroxysmal to 
persistent AF. (Allessie et al., 2001) The increasing risk of fatal AF consequences comes from 
the fact that AF is asymptomatic in more than one third of the patients. (Israel et al., 2004)  
The presence of AF worsens the prognosis in patients with cardiovascular comorbidities, 
increasing their risk for cardiovascular events, stroke, and hospitalization due to heart 
failure (RR 1,88-4,96). (Wachtel et al., 2005; Pizzetti et al., 2001; Wang et al., 2003) New onset 
AF has shown to be an independent predictor of in-hospital mortality, longer intensive care 
unit stay, and longer overall hospital stay. (Rivero-Ayerza et al., 2008) Additionally, in a 
hospital setting, AF as a comorbidity indicates worse metabolic status and poor clinical 
outcome for patients with dementia, stroke or heart failure. (Fumagalli et al., 2010) 
The road from AF to cognitive impairment and dementia can be either direct or via stroke as 
an intermediate. Silent or asymptomatic strokes are valuable predictors for clinical strokes 
and dementia, as well. The Rotterdam study showed a 3 fold risk increase for stroke, and 2,3 
fold risk increase for dementia with a steeper decline in cognitive function. (Vermeer et al, 
2003a; Vermeer et al., 2003b) Concerning pre and post stroke dementia burden, it was 
analyzed recently by Pendlebury and Rothwell in a meta-analysis that there are 10% of 
demented patients before first stoke, 10% of dementia occurred soon after first stroke and 
more that 30% after recurrent stroke. (2009)  
Lastly, it is thought that other often underdiagnosed vascular conditions like hypertension 
and ischemic heart disease or depression in the elderly will eventually lead to dementia 
development, as well. (Collerton et al., 2009). 
3. AF and stroke 
3.1 AF and increase in stroke risk 
Non-valvular atrial fibrillation (NVAF) is associated with a prothrombotic state which carries 
an increased risk for thromboembolic events.  Studies show that levels of coagulation markers 
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are still elevated even during anticoagulation therapy. Patients with chronic AF were found to 
have a higher prevalence of chronic heart failure and history of stroke, but the prevalence of 
high D-dimer levels of these patients was comparable to those with paroxysmal AF. (Sadanaga 
et al., 2010) Recent data also link the hypercoagulability of AF with decreased renal function in 
NVAF patients. By yet unclear mechanism, the reduction in residual renal function enhances 
hypercoagulability in NVAF patients. (Tanaka et al., 2009) Predictors for thrombombolic 
events in NVAF are established, and they include recent heart failure, hypertension, advanced 
age, diabetes mellitus, previous thromboembolic events, echocardiographic evidence of left 
ventricular disfunction and left atrial enlargement. (Stroke Prevention in Atrial Fibrillation 
Investigators, 1992) Increased concentrations of hemostatic markers TAT and D-dimer were 
found in patients with NVAF, linking hypercoagulability and AF. Both of these markers have 
high molecular weights, ensuring very limited excretion from the kidneys. Therefore, their 
concentrations accurately reflect intravascular fibrin formation and lysis, and not accumulation 
as a result of renal failure. Several recent studies have established a relationship between 
elevation of these markers and subsequent thromboembolic events in patients with NVAF. 
(Enata et al., 2004; Nozawa et al., 2006) Therefore, elevation of D-dimer levels despite proper 
anticoagulant treatment can predict thromboembolic and cardiovascular events in patients 
with AF. Whether these events can be prevented by increasing anticoagulant intensity still 
needs to be discovered. (Sadanaga et al., 2010)  
The risk for thromboembolic events is present even during the non-paroxysmal period in 
patients with paroxysmal AF. Plasma markers of thrombin activity (thrombin-antithrombin III 
complex-TAT), active fibrinolysis (plasmin-alpha 2-plasmin inhibitor complex-PIC), and 
platelet activity (platelet factor 4-PF4) were evaluated in the left atria (LA) of patients with 
paroxysmal AF (pAF) during the non-paroxysmal period. The results of this study showed 
elevated coagulation activity in LA of patients with pAF, even during the non-paroxysmal 
period. This is the first study to report hypercoagulability in the LA of pAF patients during 
sinus rhythm. (Motoki et al., 2009) Experiments demonstrated two coagulation mechanisms, 
one being endothelial dysfunction caused by AF, (Fukuchi et al., 2001) and oxidative stress 
induced in the LA by AF. (Dudley et al., 2005; Kim et al., 2005) This study also has clinical 
relevance since it showed increased cogulation activity in LA in pAF patients, but without 
increased platelet activity, making anticoagulation, rather than antiplatelet, a therapy of 
choice. 
3.2 AF and stroke – the studies and surveys 
Stroke is probably the most devastating complication of AF. AF is the cause of 15-20% of all 
ischemic strokes, (Go, 2005) and it increases the risk for stroke fivefold. (Wolf et al., 2001) 
Cardioembolic stroke, most of which is due to AF, is the most lethal subtype of ischemic 
stroke and has a higher risk of disability than other stroke subtypes. (Simpson et al., 2010)  
AF is also an independent risk factor for stroke severity and recurrence. (Penado et al., 2003) 
Not only do AF patients have increased post-stroke mortality and stroke recurrence, but 
they also suffer more severe strokes than their age-matched counterparts suffering strokes 
due to other aetiologies. (Marini et al., 2005; Dulli et al., 2003) AF should be considered 
when assessing cryptogenic strokes, which account for about one third of first ever ischemic 
strokes. Most likely 25% to 50% of cryptogenic strokes could be attributed to undetected AF, 
and therefore are of cardioembolic origin. (Petty et al., 1999) Unrecognized AF can also 
cause cryptogenic transient ischemic attack (TIA). (Malik et al., 2011) Namely, following 
prolonged monitoring of asymptomatic patients, 85% of AF episodes lasted less than 30 
seconds. (Tayal et al., 2008) To support this thesis, a magnetic resonance (MR) study was 
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performed on more than 2000 asymptomatic subjects. In 10,7% of participants at least one 
silent cerebral infarction could be detected; the risk for silent brain infarct is doubled in 
subjects with AF in comparison to those without AF. The Framingham Offspring Study of 
prevalence and correlates of silent cerebral infarcts (SCI) was the first one to demonstrate a 
significant relationship between AF and SCI, which has been associated with increased risk 
of incident stroke and cognitive impairment. (Das et al., 2008) As previously mentioned, 
silent strokes are, also, predictors of less favourable cognitive outcome and dementia 
occurrence. (Vermeer et al, 2003a; Vermeer et al., 2003b) For all the above mentioned 
reasons, it seems wise to develop a risk score, such as that derived from the Framingham 
Heart Study, that could help to identify risk of atrial fibrillation for individuals in the 
community, assess technologies or markers for improvement of risk prediction, and target 
high-risk individuals for preventive measures. (Schnabel et al., 2009) 
When a stroke occurs in patients with AF, the severity of the stroke is generally much 
greater, as is mortality and disability compared to those patients in sinus rhythm. 
Additionally, it seems that arrhythmia progression in isolated AF is a marker of increased 
risk for adverse cardiovascular events. (Potpara et al., 2011) Unsurprisingly, the biggest 
challenge facing physicians caring for patients with AF is the prevention of stroke and 
thromboembolism, whether as primary or secondary prevention.  
In the Euro Heart Survey, prescription of antithrombotic therapy was based on the type of 
AF and availability of warfarin monitoring clinics, rather than the stroke risk profile per se. 
(Nieuwlaat et al., 2007) However, the type of AF should not be taken into consideration, 
given that paroxysmal AF has a similar stroke risk to persistent or permanent AF in the 
presence of risk factors – therefore such patients would derive much benefit from 
anticoagulation prescription. (Tay et al., 2009)  
The National Acute Israeli Stroke Survey (NASIS) examined the potential effect of 
preadmission anticoagulation on stroke severity and outcome in patients with AF. Data 
showed that effective anticoagulation therapy is associated with decreased stroke severity, 
improved functional outcome, and better survival in patients with AF admitted with acute 
brain ischemia.  Another important finding of this study showed that the effective 
anticoagulation was not associated with an increased risk of symptomatic hemorrhagic 
transformation during hospitalization. (Schwammenthal et al., 2010) Rietbrock et al. 
evaluate stroke incidence by examining the United Kingdom General Practice Research 
Database from 1987 onwards in routine clinical practice among >51,000 chronic AF patients 
aged 40 years who were taking either aspirin or warfarin. Virtually all the patients had been 
treated with warfarin or aspirin, and almost 10,000 patients had received both: 
concomitantly or separately. Compared to no warfarin use, current and past use were both 
associated with a significant reduction in stroke rate, by 67% (RR 0,33, 95% CI 0,30–0,35) and 
44% (RR 0,56, 95% CI 0,50–0,63), respectively. The benefits were more evident amongst the 
elderly, whereby the risk of stroke was reduced by 45% in elderly warfarin users (aged 75 
years or older) and by 14% in younger users. In contrast, there was no difference in the 
stroke rate between current and past aspirin use (RR 1,04, 95% CI 0,94 – 1,15). Thus, all AF 
patients with one or more risk factors (that is, the “moderate risk” and “high risk” 
categories) should all be seriously considered for warfarin, whilst those with no risk factors 
at all (essentially, the “low risk“ category) could be considered for aspirin or no 
antithrombotic therapy. Another interesting observation from the study is that the stroke-
risk reduction was only apparent after 6–12 months of treatment, possibly reflecting poor 
INR control in the first six months. (2009) 
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Further important issue concerning AF and acute ischemic stroke is the destiny of patients 
who are causally treated with rtPA (recombinant tissue plasminogen activator) intravenous 
thrombolysis within the first 3 hours after the acute stroke onset. Previous results showed 
poor rate of early recanalization with a low rate of early major neurological improvement 
after rtPA administration. (Kimura et al., 2008) In contrast, recent encouraging results were 
reported by the Czeck multidisciplinary medical researchers. It appears that no initial 
statistical differences existed between the treated versus non-treated groups when 24 hour 
and 7 day clinical improvement or rate of achieved recanalizations were compared. 
However, AF patients had significantly poorer 90-day clinical outcome than non-AF 
patients using modified Rankin scale for comparison (median mRS 2,5 vs. 1,0). It is 
speculated that this is most likely due to more severe baseline neurological deficits or the 
greater number of arterial occlusions witnessed by the MRA before the use of intravenous 
thrombolysis. The other explanation is the physiology of clot dissolution, which depends on 
size, site of occlusion, clot composition, surface area of the clot exposed to the blood flow, 
and penetration of rtPA into the clot structure. Fresh and old clots form in the left atrium, 
but old and large thrombi may be more resistant to thrombolytic therapy than fresh and 
small ones. Therefore, it appears that AF stroke patients are more likely to have old and 
large thrombi, which are resistant to thrombolytic therapy. (Sanak et al., 2011) 
4. When to treat AF patients in order to prevent future neurological 
complications? 
The size of expected AF affected TIA and stroke patients is 15%. It seems that the most 
important factors that need to be evaluated in these patients regarding AF screening are age 
and left atrial diameter. Using this protocol about 47% of TIA and stroke patients can be 
excluded from further protocol. (Malik et al., 2011)  
Judicious use of antithrombotic therapy importantly reduces stroke for most patients who 
have atrial fibrillation. Absolute increases in major extracranial hemorrhage associated with 
antithrombotic therapy were less than the absolute reductions in stroke. Adjusted-dose 
warfarin and antiplatelet agents reduce stroke by approximately 60% and by approximately 
20%, respectively, in patients who have atrial fibrillation. Warfarin is substantially more 
efficacious (by approximately 40%) than antiplatelet therapy. (Hart et al., 2007) 
4.1 Patient selection 
Over the last 15 years of so, the various published stroke risk schema only have modest 
predictive value for thromboembolism, with no improvement in predictive ability over the 
years. (Lip & Halperin, 2010) Many stroke risk assessment schema classify a large 
proportion of subjects into the ‘moderate risk’ category where treatment guidelines 
recommend either warfarin or aspirin, and risk stratification schema that result in 
classification of a large proportion of AF subjects into the ‘moderate risk’ category could 
potentially be less useful in everyday clinical practice, since current treatment guidelines 
recommend the use of either warfarin or aspirin in such patients, causing confusion over 
which therapy should really be prescribed. Alternatively, classification as ‘moderate risk’ is 
often used as an excuse not to give anticoagulation, since the guidelines ‘allow’ aspirin. 
Given the modest predictive ability for identifying ‘high risk’ subjects and the availability of 
new oral anticoagulant drugs that overcome the shortcomings of warfarin, stroke risk 
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stratification schema perhaps need to focus more on identifying the ‘truly low risk’ category 
of patients where no antithrombotic therapy may even be an option, given the increasing 
debate over the effectiveness of aspirin and potential for harm. (Sato et al., 2006)  This 
concept was first proposed by van Walraven et al. and more recently revisited by Lip and 
Halperin. (van Walraven et al., 2003; Lip & Halperin, 2010) 
In selecting the appropriate strategy to prevent stroke in an individual patient with AF, 
clinicians must consider the patients’ risk of stroke, their risk of bleeding, concomitant 
indications for either anti-platelet medications or oral anticoagulants (OAC), anticipated 
challenges with INR control and patient preference. One of the most frequently used 
assessment tools by American Cardiologists is the CHADS2 score grouping the patients into 
low- (score 0 to 1), intermediate- (score 2 to 3), or high- (score 4 to 6) risk category. However, 
European Society of Cardiology prefers the use of CHA2DS2-VASc score. Its components are 
as follows: C – congestive heart failure/LV dysfunction, H – hypertension, A – age ≥ 75 
years, D – diabetes mellitus, S – stroke (TIA/ thromboembolism - TE), V – vascular disease, 
A – age 65-74 years and S – sex (female); and lower case numbers representing items with 
greater weight. The second score is more sensitive to a greater number of vascular risk 
factors and lowers the cut off value for treatment initiation making it therefore a future 
strategy for more refined stroke risk lowering schema: those at truly low risk (CHA2DS2-
VASc = 0) who need not be prescribed any antithrombotic therapy, while all others 
(CHA2DS2-VASc score ≥1) can be considered for anticoagulation.(Table 1.)  
 
 CHADS2   Score CHA2DS2-VASc  Score 
Congestive 
heart failure   
 1  Congestive heart failure/LV dysfunction  1 
Hypertension   1  Hypertension   1  
Aged ≥75 years   1 Aged ≥75 years   2  
Diabetes mellitus  1 Diabetes mellitus  1 
Stroke/TIA/TE  2 Stroke/TIA/TE  2 
Maximum score   6  Vascular disease (prior MI, PAD, or aortic plaque)  1 
    Aged 65-74 years  1 
    Sex category (i.e. female gender)  1 
    Maximum score  10   
Table 1. The CHADS2 and CHA2DS2-VASc score table 
Not less important, is the need to select those patients who are truly at low bleeding risk, 
and therefore a HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding 
history or predisposition, Labile International Normalized Ration, Elderly, Drugs/alcohol 
concomitantly) simple risk assessment score was proposed where score over 3 points 
indicates „high risk“ requiring regular and more frequent check-ups. (Lip, 2011) 
4.2 Oral anticoagulation therapy 
Weighing all of these, anti-platelet therapy is the most appropriate strategy for many 
patients. Using either of the two aforementioned scales, OAC are advised if the score is ≥ 2.  
Furthermore, recent study reported that significantly elevated plasma C-reactive protein 
levels were noted in the high-risk group compared to those in the intermediate- and low-
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risk groups; and the use of transoesophageal echocardiography, the incidence of left atrial 
spontaneous echo contrast and left atrial thrombus increased with an increasing CHADS2 
score. (Maehama et al., 2010)  
As for AF treatment and stroke, strokes due to AF are largely preventable with warfarin 
therapy, and that results in a 64% relative risk reduction. (Hart et al., 2007) Furthermore, 
recent observational study found out that it is even more beneficial if the INR was 
maintained at 1,8 (range 1,5-2,0) than at the standard target of 2,5. (Pengo et al., 2010) In 
addition to its established benefit for stroke prevention, effective anticoagulation therapy is 
associated with decreased stroke severity and better functional outcome and survival in 
patients with AF presenting with acute brain ischemia. (Schwammenthal et al., 2010) Sadly, 
many times anticoagulation for stroke prevention was found underused in general for 
patients with AF, and even in such high-risk groups as patients with stroke. However, 
participation in special quality improvement programs, like Get-With-The-Guidelines-
Stroke (GWTG-S) was associated with improved adherence for patients with ECG-
documented AF; still patients with a history of AF alone were largely untreated. (Lewis et 
al., 2009) 
Additional oral treatment choices may soon be available for patients with AF, which would 
be particularly useful for patients in whom OAC is not used because of poor INR control, 
inability to comply with INR monitoring or drug-interactions. Both oral direct thrombin 
inhibitors and factor Xa inhibitors, like endoxaban, overcome these limitations of warfarin 
and may find a role in stroke prevention among these groups of patients, who are typically 
treated with anti-platelet agents. (Healy, 2009) The advent of novel oral direct-thrombin 
inhibitors and Factor Xa inhibitors with their more stable pharmacokinetic profiles, removal 
of the need for INR monitoring, and fewer patient-related barriers (diet, alcohol and drug 
interactions, INR control, etc.) that currently limit prescription of anticoagulation, may 
increase the unmet need of anticoagulation and make anticoagulation available and safe to 
those patients who may stand to derive benefit from it, including those with a CHADS2 
score of 1. (Lane & Lip, 2010) 
4.3 Antiplatelet  therapy 
For the 22% of AF patients with a CHADS2 score of 0, the low observed risk of stroke makes 
aspirin the preferred treatment option. (Lee et al., 2010) Given the slightly higher stroke risk 
among the 32% of AF patients with a CHADS2 score of 1, aspirin, the combination of aspirin 
plus clopidogrel and OAC are all appropriate options, with the ultimate choice between 
therapies hinging on patient preference, bleeding risk and concomitant indications for one 
of these therapies. For patients who are at higher risk of stroke, but who cannot or will not 
take OAC; the combination of aspirin plus clopidogrel has now been shown to provide 
greater protection against stroke than aspirin alone. Finally, for OAC-treated patients who 
cannot achieve good INR control, combination anti-platelet therapy may be a safer and 
equally effective alternative to OAC. (Lee et al., 2010)  
4.4 Mechanical devices 
Recently, Ohara et al. have shown that the severity of blood stasis in the left atrium was 
greater in chronic AF patients than in paroxysmal AF patients at the comparable risk level 
and that severity of blood stasis in the LA and aortic atherosclerosis correlates with an 
accumulation of clinical risk factors for thromboembolism in non-valvular AF patients. 
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(2010) Furthermore, enhanced coagulation activation appears to be related to a reduction in 
residual renal function in patients with non-valvular AF patients which suggests that 
decreased renal function might be a candidate predictor of thromboembolic events in those 
patients. (Tanaka et al, 2009) 
However, since more than 90% of atrial thrombi originate from the left atrial appendage 
(LAA), the devices that can isolate this structure from the systemic circulation perhaps may 
obviate the need for long-term anticoagulation therapy. Namely, the PLAATO device 
(Percutaneous Left Atrial Appendage Transcatheter Occlusion; Appriva Medical, CA, USA), 
later withdrawn by the manufacturer in 2006 or the WATCHMAN system (Aritech Inc, 
MN,USA), which is a self-expanding nitinol frame structure. Newer oral anticoagulants (eg, 
the oral direct thrombin inhibitors) or even the isolated use of antiplatelet therapy is 
necessary after device implantation, in addition to refinements in stroke and bleeding risk 
stratification. Still, not all thrombi originate from the LAA, with up to a quarter of strokes in 
patients with atrial fibrillation caused by cerebrovascular disease and complex 
atheromatous plaques involving the aorta and carotid arteries, or other cardiac sites. 
(Wrigley & Lip, 2009) Another important concern is the development of cardioembolic 
stroke, a serious periprocedural complication of radiofrequency catheter ablation and it may 
cause long-term neurocognitive and functional impairment resulting in significant disability 
or mortality on its own. Most periprocedural clinical events occur during or within 48 hours 
of the procedure with the incidence of 1–6% for focal ablations and up to 7% for linear AF 
ablations depending on the implemented anticoagulation strategy and the method of 
assessment. However, once successfully implemented, at 1 year follow-up interval, 
complete functional and neurocognitive recovery is expected. (Patel et al., 2010)  
4.5 Hypertension treatment 
Blockade of the renin–angiotensin system is an important approach in managing high blood 
pressure, and has increasingly been shown to affect cardiovascular disease processes 
mediated by angiotensin II throughout the cardiovascular and renal continua. It seems that 
new-onset AF and associated stroke were significantly reduced by losartan- compared to 
atenolol-based antihypertensive treatment with similar blood pressure reduction in the LIFE 
study. (Wachtel et al., 2005) Additionally, clinical evidence was found in favor of telmisartan 
and reduction of left ventricular hypertrophy, arterial stiffness and the recurrence of atrial 
fibrillation, as well as renoprotection. (Galzerano et al., 2010)  
4.6 Inflammation 
In recent years data to support the notion that inflammation plays a role in the pathogenesis 
of AF are increasing. Many ongoing studies are attempting to attenuate these inflammatory 
processes in patients with AF by novel therapeutic strategies, such as the use of 
glucocorticoids. However, systemic glucocorticoid use itself has been linked to increased 
risk of AF. Therefore, more research is necessary to determine whether these drugs are a 
potential treatment or risk factor for AF. (Rienstra & Van Gelder, 2010)  
4.7 Quality of life surveys 
Lastly, but not least important is, side to side with therapeutic effects, the health-related 
quality of life considered by the patient (HRQoL) at baseline and after potential therapeutic 
intervention. Most often this is achieved with the use of Short-Form health survey-36 items 
that does not seem to be proficient enough and formation of standardized AF-specific 
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questionnaires is warranted. So far, two main therapeutic options follow either rate-control 
or rhythm-control and neither has been proven significantly better than the other, yet both 
improve HRQoL, so the choice of which pharmacologic agent to prefer could be personally 
tailored to each patient by such questionnaire. (Fuster & Mearns, 2010) 
5. AF and dementia 
Dementia prevalence increases with age, from 5-8% over 65 years of age to 25-50% over the 
age of 85 years. (Collerton et al., 2009; Luchsinger, 2010) The Rotterdam Study showed that 
dementia occurred twice as common in subjects with AF (more so if subject age was less than 
75 years of age and if they were women), and a significant positive association between 
cognitive impairment and AF was confirmed (no age association was discovered). And, even 
though AF proved to be commonly discovered in AD and VAD patients, it is more strongly 
associated with AD incidence. (Ettore et al., 2009) The greatest reason for missing AF diagnosis 
is that a single ECG is usually ordered for acute stroke patients, thereby causing those with 
paroxysmal AF to elude from screening and diagnosis. (Kamel et al., 2009). There is no 
evidence of putative mechanisms of direct relation between dementia and AF, because AF is 
found in all types of dementia-vascular, Alzheimer and mixed types of dementia which are 
results of different pathomorphological and pathophysiological mechanisms. 
The onset of dementia goes unnoticed in the early stages, sometimes symptoms such as 
cognitive and intellectual impairment as well as carrying out everyday activities may 
became apparent only in the mid-to-late stages. Symptoms of dementia include: memory 
loss, confusion, forgetfulness, poor concentration, inability to cope with everyday activities, 
language impairment, slurred speech, inability to follow simple instructions, inappropriate 
laughing and crying, behavioral changes, impaired social skills, eating problems, a shuffling 
or jerky gait, incontinence and/or lack of bowel control. Lateralizing signs such as 
hemiparesis, bradykinesia, hyperreflexia, ataxia, pseudobulbar palsy, and gait and 
swallowing difficulties may also be observed. (Vermeer et al., 2003; Velandai et al., 2006) 
Several specific diagnostic criteria can be used to diagnose vascular dementia: Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, International 
Classification of Diseases, Tenth Edition criteria, National Institute of Neurological 
Disorders and Stroke- Association International pour la Recherché & L'Enseignement en 
Neurosciences (NINDS-AIREN) criteria, The Alzheimer's Disease Diagnostic and Treatment 
Center criteria, The Hachinski ischemic score. In evaluation of dementia patients 
neuroimaging methods should, also, be included as well as evaluation of specific serum and 
cerebrospinal fluid markers for AD. A number of neuroimaging candidate markers are 
promising, such as hippocampal and enthorinal cortex volumetry, basal forebrain nuclei 
assessment, cortical thickness, deformation based and voxel based morphometry, diffusion 
tensor imaging tractography and functional magnetic resonance imaging. For example, 
combined measurements of the cerebrospinal fluid (CSF) t-tau, Aβ42 and p-tau profile and 
regional flow or mediotemporal lobe atrophy demonstrate higher predictive power than 
either diagnostic approach alone in cognitive impairment evaluation. Differential diagnosis 
between AD and vascular dementia seems promising by using the ratio of Aβ42 and p-tau, 
between AD and Lewy bodies dementia by using the ratio of Aβ peptides of varying lengths 
(Aβ42/ Aβ38 and Aβ42/ Aβ37) and tau protein. Other interesting novel biomarker 
candidates derived from blood and CSF are being currently proposed (phase I or II of 
multicenter studies).  
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Magnetic resonance imaging (MRI) can provide a detailed image of the brain and 
cerebrovascular system. However, the structural changes detected with MRI as well as the 
biomarkes do not accurately predict the clinical manifestation of cognitive impairment so 
cognitive testing is imperative. (Rockwood et al., 2009) 
5.1 Dementia syndromes 
Progression of Alzheimer dementia (AD) is highly variable. Most estimates derive from 
convenience samples from dementia clinics or research centers where there is substantial 
potential for survival bias and other distortions. Nowadays, there is a growing rise in public 
health concern due to lack of effective curative treatment and raising prevalence with 
variable survival rate of the two most frequent dementia syndromes (gloomy results report 
survival rate for men with AD 4,1 years and for women 4,6 years; while five year survival 
rate for VAD is 39%). (Tschantz et al., 2011)  
AF in connection with dementia is usually analyzed through most common types of 
dementia: Alzheimer's disease (AD), vascular dementia (VAD) and mixed dementia (MD). 
When AF is regarded in the pathophysiology of stroke or dementia, it must be said that AF 
can result in either cardiac thromboembolism or reduced cardiac output and cerebral 
hypoperfusion with main neuroradiological manifestation such as white matter lesions 
(WML). WML are a frequent finding in patients with vascular cognitive impairment, AD 
and VAD. WML are reported to be up to three-fold more prevalent in patients with AD. 
(Vermeer et al., 2003a) Furthermore, lacunar state, in which numerous lacunae indicate the 
presence of severe widespread small vessel disease, is another observed manifestation in AF 
patients. (Vermeer et al., 2003b)  
By far, the most common type of dementia is AD accounting for 60-80% of all dementia 
patients, and having the greatest prevalence among all neurological diseases. AD is defined 
by the World Health Organization (WHO) as a degenerative brain syndrome characterized 
by progressive decline in memory, thinking, comprehension, calculation, language, learning 
capacity and judgment sufficient to impair personal activities of daily living. Today, it is 
believed to be associated with excessive extracellular beta-amyloid and intracellular 
hyperphosphorylated tau protein accumulation eventually leading to the loss of cholinergic 
neurons and relative glutamate excess. (Rocchi et al., 2009) 
VAD, accounting for 10-20% of all dementia patients, is characterized by a stepwise 
deteriorating course and a patchy distribution of neurologic deficits (affecting some functions 
and not others) caused by cerebrovascular disease. It is not a single disease, but rather a group 
of syndromes relating to different vascular mechanisms. Common risk factors for VAD are the 
ones already recognized for cerebrovascular disease – non-modifiable risk factors such as age, 
gender, race/ethnicity, genotype, previous myocardial infarction, and TIA or stroke; and 
modifiable risk factors like diabetes, hyperlipidemia, arterial hypertension, atrial fibrillation, 
coronary and or peripheral artery disease, obesity, physical inactivity, stress, alcohol 
consumption, and smoking. (Luchsinger, 2010; Llewellyn et al., 2008) 
Subtypes of vascular dementia include: mild cognitive impairment, multi-infarct dementia 
(MID), strategic infarct dementia, subcortical ischemic dementia, ischemic-hypoxic 
dementia, and haemorrhagic dementia. (Grand et al., 2011)  
The term mild cognitive imparement (MCI) refers to a transitional stage between cognitive 
changes of normal aging and vascular dementia. At this stage, cognitive decline is not 
severe enough to constitute dementia, but also it is beyond the cognitive functioning deficit 
which is expected in normal aging. Patinets with MCI have subjective memory complains 
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which are relative to age and education norms, but essentially normal general function as 
well as activities of daily living. Patients with MCI progress to dementia at a rate of 10-15% 
per year, far higher than the baseline rate of 1-2% per year in normal elderly. In cases of MCI 
an elderly patient will come in complaining of memory lapses, and will want to know if 
they have “normal” age related memory loss or something more serious. In everyday 
evaluation of cognitive changes most neurologists and psychiatrists rely on the Folstein 
Mini Mental State Exam (MMSE). But the MMSE has some serious limitations- it is quite 
sensitive at picking up moderate to severe dementia, it is very poor at screening for patients 
with MCI. Both, normal and MCI patients will typically score 26 or above, the usual cut-off 
point for cognitive impairment. The Montreal Cognitive Assessment (MoCA) appears to 
work much better in such cases. The test was developed specifically to better diagnose MCI, 
it is a more challenging version of the MMSE. It is quick to administer (about 10 minutes) 
and has a maximum of 30 points. In a study comparing the MMSE with the MoCA, the 
MMSE had a sensitivity of only 18% to detect MCI (meaning it missed 82%, while the MoCA 
detected 90% of MCI subjects). As always, though, high sensitivity comes at the price of 
somewhat lower specificity- the specificity for MCI was 87%, meaning that 13% of actually 
normal people will be falsely labeled as impaired -- still quite accurate. (Nasreddine ZS, 
2005: Dong Y et al., 2010) 
MD is dementia consisting of features proving the coexistence of AD and VAD either 
clinically or based on neuroimaging evidence of cerebral ischemic lesions. It is thought that 
vascular processes in both disorders mutually induce each other. To support such thesis, the 
following shared risk factors are secluded: hypertension, adult onset diabetes mellitus, 
atherosclerosis, AF and smoking. Lastly, MD is more common among the old elderly (85+), 
and can be definitely proven solely on autopsy. (Ferriet al., 2005; Collerton et al., 2009)  
5.2 Vascular cognitive impairment 
Apart from the three previously mentioned dementia syndromes, newly arising topic 
concerning dementia is vascular cognitive impairment (VCI) that inclines toward 
substituting “Alzhemerized” dementia concept in the setting of cerebrovascular disease 
with a spectrum of cognitive deficits that are all of vascular origin. The pyramid of cognitive 
decline in this setting initiates with condition known as the “brain at risk”, perisymptomatic 
changes, VCI, white matter lesions (WML) and lacunae, and, lastly, VAD. It is important to 
acknowledge that vascular diseases can cause focal (usually due to thrombosis or embolism) 
or diffuse (usually due to hypertension) effects on the brain that may eventually lead to 
cognitive decline. However, both mechanisms are frequently present in the same patient.  
Unfortunately, up to date there are no resolute clinical criteria for VCI, still the common 
clinical finding is progressive gait alteration and incontinence. (Battistin & Cagnin, 2010) 
And recently, there is a growing interest in the clinical and scientific area involving the 
elderly community in investigation of elderly fallers. Interestingly, recurrent fallers had 
lower MMSE scores than single fallers or non-fallers. (Vassalo et al., 2002) Areas of higher 
cortical function that showed the most deterioration were: attention and calculation, 
registration (short term memory), recall and praxis (visuospatial perception). (Chen et al., 
2010) Chen et al. have isolated independent factors to be history of dementia, stroke or AF 
or prolonged hospital stay (> 5 weeks). (2010)  
5.3 AF, stroke and dementia 
Reported estimates of the prevalence of dementia are consistent: 10% of patients had 
dementia before first stroke, 10% developed new dementia soon after first stroke, and more 
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than a third had dementia after recurrent stroke. The strong association of post-stroke 
dementia with multiple strokes and the prognostic value of other stroke characteristics 
highlight the central causal role of stroke itself as opposed to the underlying vascular risk 
factors and, thus, the likely effect of optimum acute stroke care and secondary prevention in 
reducing the burden of dementia. (Pendlebury & Rothwel, 2009) 
Pendlebury and Rothwel, stated that stroke characteristics determined patient’s 
predisposition towards dementia rather than the underlying vascular risk factors. Namely, 
most important risk factors in prestroke dementia were medial temporal lobe atrophy, 
female sex and family history of dementia; while in poststroke dementia the most important 
was the presence of multiple cerebral lesions in time and place. (2009) Vascular risk factors 
for AD include stroke, hypertension, diabetes, homocysteine, smoking, 
hypercholesterolemia, heart failure and AF; it is possible that these can trigger 
cerebrovascular dysfunction and AD pathology. Explanations for these associations include 
the coincidence of common disorders in the elderly where vascular and cerebrovascular 
disease can precipitate AD, implying that the onset of dementia disease is determined by a 
synergistic combination of risk factors. (de Toledo Ferraz Alves et al., 2010) Additionally, 
many vascular risk factors for AD, such as atherosclerosis, stroke and cardiac disease in the 
aging individual, could result in cerebrovascular dysfunction and trigger AD pathology. A 
major vascular susceptibility factor gene is the apolipoprotein E gene, found to be associated 
with sporadic late-onset AD cases. Another interesting vascular susceptibility gene is 
angiotensin converting enzyme (ACE). Other possible genes include VLDL-R, LRP,  NOS3, 
CST3, OLR1, MTHFR, PON1 and VEGF, but many of the related studies have shown 
conflicting results. (Rocchi et al., 2009) 
Some strokes are clinically detected, while others go undetected. Silent strokes are, also, 
associated with higher age, elevated blood pressure and AF. (Vermeer et al., 2003a) It is 
important to stress that apart from silent strokes, AF itself can, also, occur silently thus 
posing great threat to our aging society. (Aliot, 2009) The presence of AF increases the risk 
for stroke, about 20% of all embolic strokes are associated with it. (Ratcliffe & Wilcock, 1985) 
There is increasing evidence that AF is associated with an increased risk of asymptomatic or 
silent cerebral infarction and as a result may confer an increased risk of progressive 
cognitive impairment. Most cases of AF are now of non-rheumatic or non-valvular (NVAF) 
aetiology. NVAF confers a fivefold increased risk of clinically apparent stroke compared to 
those patients, still in sinus rhythm. Silent cerebral infarctions are not associated with the 
nature (chronic/paroxysmal) or duration of atrial fibrillation. This may be so due to the fact 
that the risk of stroke for people with silent brain infarcts is comparable with the risk of TIA 
patients, of whom approximately 20% develop stroke within 4 years. (Vemeer et al., 2003) 
Recently, AF was associated with the hazard ratio of 1.8 (95%CI, 1,0-3,4) for first-ever stroke, 
but not significantly associated with dementia or AD. (Marengoni et al., 2009) However, 
brain reserve appears to be protective in case of stroke with favourable outcome measures 
such as younger age, higher premorbid IQ, no AF, no dementia, less apathy and fewer 
intercurrent cerebrovascular events. (Withall et al., 2009)  
5.4 Dementia treatment 
Treatment of dementia rests on a two-pronged approach: modification of the underlying 
disease (risk factors) and prevention and treatment of dementia symptoms. Goals of 
pharmacotherapy should be: primary and secondary prevention of cognitive changes in AF 
patients, reduction of present cognitive changes with acceptable side effects of 
pharmacotherapy, and restoration/improvement in functional measures and quality of life. 
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Various potential risk or preventive factors for vascular dementia have been suggested by 
epidemiologic research: lifestyle changes, including diet, physical activity and stress 
reduction as well as pharmacological strategies such as antihypertensive drugs, statins, 
antiplatelet, anticoagulant therapy, antidiabetic drugs, insulin, hormone replacement 
therapy, NSAID (nonsteroidal drugs), Ginko biloba, ENADPH, donepezil, galantamine, 
memantine, rivastigmine, cyclandelate, hyderginepentoxifylline, CDP choline. Meta 
analyses have shown that long-term use of NSAID reduces risk of dementia, and the type of 
NSAID is important – the best drugs contain acetylsalicylic acid in low concentrations (75-
100 mg). Ginko Biloba was proven to be useful in secondary prevention of cognitive decline. 
Anticoagulant therapy is recommended in patients with atrial fibrillation.  
WARIS II (Warfarin-aspirin reinfarction study) has shown that aspirin is better than 
warfarin in stroke risk reduction in diabetic patients with recurrent strokes. WASPO 
(Warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation), 
BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged Study), ACTIVE W (Atrial 
fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular events-W) have 
shown that warfarin is still the best in prevention of vascular events in patients with atrial 
fibrillation (even in age more 75). RE-LY (Randomized Evaluation of Long Term 
Anticoagulant Therapy) study has shown that new drug Dabigatran (DTIs) is superior to 
warfarin with lower number of complication in prevention of CVD. ROCKET AF 
(Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K 
antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) study has 
shown similar results. (Bowler JB, 2007; Rockwood et al., 2009) Nonaticoagulant strategies to 
prevent CVD in AF patients should include: left atrial appendage surgical excision, left atrial 
appendage percutaneous occlusion, catheter ablation or treatment with dronedarone 
(amiodarone). (Patel D et al., 2010)  
5.5 Use of anticoagulants among the demented 
Anticoagulation for stroke prevention seems to be underused in elderly patients with 
nonvalvular AF and those with falls and/or early dementia are thought to be at a particular 
risk for stroke and hemorrhage. Jacobs et al. have performed a retrospective observational 
study using CHADS2 score and outcome events at 12 months concluding that geriatric 
population with chronic AF, including patients with falls and/or dementia, who were 
prescribed warfarin (85%) and consequently had low rates of stroke, hemorrhage, and death 
at 12 months despite a low time-in-therapeutic range. However, patients with falls and/or 
dementia had had a high mortality rate (~45%). (2009) 
Additionally, it needs to be said that despite growing evidence linking cognitive impairment 
to vascular risk factors, only a minority of clinical practice therapeutic guidelines consider 
cognition as either an adverse outcome or a factor to be considered in their treatment. 
(Rockwood et al., 2009) Regarding AF treatment, Flaker et al. have recently shown that less 
effective anticoagulation indicates more vascular events and greater cognitive dysfunction, 
and that low MMSE scores select those patients that have to apply strict therapeutic regime 
to improve their outcome. (2010) A study by Ali et al. proved that less than 50% of AD 
patients taking oral anticoagulation were within therapeutic targets. Furthermore, the 
presence of AF is associated with poor performance on neuropsychological testing, 
regardless of the actual duration of AF in a particular patient. Subcutaneus heparin in 
patients with AF is superior because of its bioavailability, but its mode of administration 
and long-term risks makes its use non-feasible. Antithrombotic agents such as aspirin or 
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clopidogrel are not widely used, despite proven clopidogrel’s greater efficacy, while the two 
combined in the ACTIVE study caused its premature cessation due to increased number of 
vascular events incidence.(Ali et al., 2006)  Most promising therapeutic agents today seem to 
be direct thrombin inhibitors (ximelagatran, argatroban and dabigatran) that appear to be at 
least as effective as warfarine, but require no monitoring while having great bioavailability. 
(Spinler, 2010)  
6. AF and arterial stiffness  
Stiffening in the large central arterial system, such as the aortic tree, significantly contributes 
to cardiovascular diseases in elderly and is positively associated with systolic hypertension, 
coronary artery disease, stroke, heart failure and AF.  ( Shirwany & Zou, 2010) Namely, 
Mitchell et al. have published that increased pulse pressure (reflection of aortic stiffness) 
increases cardiac pressure load and thus may lead to an increase new-onset AF risk. (2007) It 
is becoming clear that we need to address the problem of AF detection among patients with 
transient ischemic attack (TIA) or stroke in order to prevent further clinical events from 
occurring. The expected size of affected population is about 15% according to Malik et al. 
(2011) The most important factors that need to be evaluated are: left atrial diameter, age and 
diagnosis of stroke, while history of smoking seems to be inversely related. Sensitivity of 
testing was high (85,5%) and specificity rather low (53,1%), but still about 47% of TIA and 
stroke can be excluded from further AF screening examination using this protocol. (Malik et 
al., 2011)  
Arterial stiffness (AS) as a measurement of altered vascular mechanics is considered to play 
a key role in the pathophysiology of the cardiovascular system. Clinical conditions mostly 
predisposing to AS increase are hypertension, dyslipidemia and diabetes with metabolic 
syndrome that engulfs all of the three mentioned conditions. (Lakatta & Levy, 2003a) There 
is, also, evidence that elevated homocysteine in hypertensive individuals or those with 
isolated office hypertension plays an important role; and that aortic stiffness is associated 
with estrogen receptors alpha (ESR1) and beta (ESR 2), and not with estrogen aromatase 
(CYP19A1). (Vyssoulis et al., 2010; Peter et al., 2009) Finally, a study by Midei and Matthews 
discovered that adolescents with higher attachment anxiety and total hostility have greater 
pulse wave velocity, which is even more apparent among black individuals. (2009) 
Important information can be gained through brain CT imaging in which the presence of 
cortical infarction suggests the presence of severe ipsilateral carotid stenosis or atrial 
fibrillation thereby modifying clinical classification, patient investigation and prognosis. 
(Mead et al., 1999) It seems that small striatal infarct and the presence of high levels of brain 
amyloid will point to those most prone for the development of cognitive impairment and AD 
dementia development compared to individuals with just one or the other. This increased risk 
is supported clinically by adult onset of diabetes mellitus, hypertension, atherosclerosis and 
atrial fibrillation. (Cechetto et al., 2008) Still, severe age related changes in white matter 
independently and strongly predict rapid global functional decline. (Inzitari et al., 2009)  
6.1 Arterial stiffness (AS) indexes 
Most repeatedly mentioned indexes of arterial stiffness in the literature are: beta stiffness 
index, pulse wave velocity, augmentation index and analysis of characteristics of central 
blood pressure waveform. And, it seems that two most important factors affecting arterial 
stiffness increase, such as increasing age and blood pressure, affect the fibrotic components 
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of the extracellular matrix, such as elastin, collagen and fibronectin. (Lakatta & Levy, 2003a) 
Lately, even tissue Doppler measuring left ventricular systolic dysfunction is used to 
indicate increased arterial wave reflection. (Russo et al., 2011)  
Carotid artery stiffness was found not to be an independent risk factor or predictor of 
vascular events in patients with manifest arterial disease, but it may prove useful for 
selection of those patients with lesser risk when evaluated together with low systolic blood 
pressure. (Dijk et al., 2005) A recent study indicated that central arterial stiffness, usually 
represented by descendent thoracic aorta stiffness and atheroma presence as expressed by 
beta stiffness index, can be correlated to and represented by radial augmentation index. 
(Sako et al, 2009) Lastly, vascular stiffness was found to be inversely related to cognitive 
function, and greater in VaD compared with AD. Using pulse wave velocity may be useful 
in identifying VaD. (Rabkin & Jarvie, 2011) 
Mitchell et al. have recently published that increased pulse pressure (reflection of aortic 
stiffness) increases cardiac pressure load and may increase AF risk. The association between 
pulse pressure and AF persisted in models that adjusted for baseline left atrial dimension, 
left ventricular mass, and left ventricular fractional shortening. Interestingly, in models 
adjusted for age, sex, and clinical risk factors for AF (elevated body mass index, history of 
smoking, valvular disease, diabetes mellitus, left ventricular hypertrophy, hypertension 
treatment, and myocardial infarction or heart failure), mean arterial pressure was unrelated 
to incident AF.  
It seems that ultrasonographic measurement of AS can be chosen as sensitive for detection 
of vascular damage prior to IMT (intima-media thickness) increase at all ages. (Nunez et al., 
2010) Additionally, glycemic status appears to be independently associated with impaired 
endothelial function and increased arterial stiffness using multivariate analysis, among 
sensitive population leading to abnormal vessel wall characteristics and more small vessel 
disease-related cerebrovascular events in stroke survivors. (Gunarathne et al., 2009) 
AS indexes may be regarded as quick, undemanding, and bed-side premorbid diagnostic 
tools, used as markers or predictors, for the assessment of life and disability threatening 
neurological conditions such as stroke or dementia in the setting of altered vascular 
mechanics and AF. Furthermore, perfusion enhancement, monitored by AS parameters, 
seems to produce a favourable and consistent response in AD patients, unlike other more 
often used dementia therapeutic  regimes, offering a new and powerful window for AD 
treatment. (London et al., 2004; Hirata et al., 2005; Williams et al., 2006)  
6.2 Is there treatment for altered arterial stiffness?  
Recently, in order to influence cerebral perfusion and consequently arterial stiffness, the 
most favourable treatments were mentioned: calcium channel blockers, diuretics and ACE 
inhibitors. (London et al., 2004; Hirata et al., 2005; Williams et al., 2006) Additionally, newer 
beta blockers, with supplementary vasodilating properties, showing favourable effects on 
carbohydrate and lipid metabolism, endothelial function and on oxidative stress, also, 
indicated substantial positive therapeutic effect. (Agabiti-Rosei et al., 2009)  
It is important to acknowledge that beta-blockers and diuretics act mostly on macro-
vasculature, while ACE inhibitors and calcium entry blockers show microvascular 
favourable actions along with improvement of large artery mechanics and reduction of 
central wave reflections. (Rizzoni et al., 2009)  
Opposed to this, statins were not proven to have any beneficial effects outside the treatment 
of hyperlipidemia and atherosclerosis. Sex difference of AD incidences between men and 
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women may be attributed to better pharmacological treatment of men versus women. (Beri 
et al., 2009) 
7. Conclusion  
Since vascular disorders are regarded as being preventable, early detection and accurate 
diagnosis of such conditions are very important clinical issues. AF plays in important role in 
future stroke risk and dementia risk. Namely, consistent evidence supports an association 
between AF and increased incidence of dementia in patients with stroke. Still, potential 
association between AF and incident dementia in mild cognitive impairment requires 
further investigation. AS provides a tool for vascular mechanics assessment and thus offers 
a window of opportunity for early treatment and diversion of overt clinical vascular events.  
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